Abstract
Azidothymidine (AZT) is an antiretroviral drug that affects cell proliferation, apoptosis, and the NF-κB pathway. As multiple myeloma (MM) presents with constitutive activation of NF-κB, we analyzed the effect of AZT on human MM cell lines. We evaluated the cytotoxic effect of AZT in human MM cell lines sensitive (8226/S) or resistant to doxorubicin (8226/DX5) and human T cell lymphoblast-like cells, uterine sarcoma cells, and HUVEC using MTT assay. Cytotoxicity was also evaluated in vivo in nude mice xenografted with 8226/S tumor. The effect of AZT on the expression of genes involved in cell proliferation, apoptosis, angiogenesis, and the NF-κB pathway was analyzed in the xenografts using real-time polymerase chain reaction. AZT was effective against both 8226/S and 8226/DX5 cells in a dose and time-dependent manner (p = 0.02) in vitro and promoted cell cycle arrest in S phase in these cells. The tumor volume was lower in mice treated with AZT compared to untreated mice (p = 0.0003). AZT down-regulated the pro-proliferative genes encoding AKT1, MYC, STAT1, MAPK8, MAPK9, CCL-3, Bcl-3, and cyclin D2; pro-angiogenenic genes encoding VEGF and IL8; and genes involved in cell adhesion (ICAM1 and FN1) and the NF-κB pathway. AZT up-regulated the expression of tumor suppressor gene FOXP1 and the pro-apoptotic genes encoding BID, Bcl-10, and caspase-8. Thus, we demonstrated the cytotoxic effect of AZT in human MM cell lines for the first time. Our data may provide the rationale for future clinical trials of AZT for treating MM.
Keywords: Multiple myeloma, Zidovudine, Cell proliferation, Apoptosis, Angiogenesis, Cytotoxic, Trizol, bortezomib, NF-kB/2, FOXP1
Anti-Cancer Agents in Medicinal Chemistry
Title:Azidothymidine is Effective Against Human Multiple Myeloma: A New Use for an Old Drug?
Volume: 13 Issue: 1
Author(s): Juliana Pereira, Debora Levy, Jorge L.M. Ruiz, Graciela A. Brocardo, Kleber A. Ferreira, Renata O. Costa, Rodrigo G. Queiroz, Durvanei A. Maria, Abrahao E. Hallack Neto, Dalton A.F. Chamone and Sergio P. Bydlowski
Affiliation:
Keywords: Multiple myeloma, Zidovudine, Cell proliferation, Apoptosis, Angiogenesis, Cytotoxic, Trizol, bortezomib, NF-kB/2, FOXP1
Abstract: Azidothymidine (AZT) is an antiretroviral drug that affects cell proliferation, apoptosis, and the NF-κB pathway. As multiple myeloma (MM) presents with constitutive activation of NF-κB, we analyzed the effect of AZT on human MM cell lines. We evaluated the cytotoxic effect of AZT in human MM cell lines sensitive (8226/S) or resistant to doxorubicin (8226/DX5) and human T cell lymphoblast-like cells, uterine sarcoma cells, and HUVEC using MTT assay. Cytotoxicity was also evaluated in vivo in nude mice xenografted with 8226/S tumor. The effect of AZT on the expression of genes involved in cell proliferation, apoptosis, angiogenesis, and the NF-κB pathway was analyzed in the xenografts using real-time polymerase chain reaction. AZT was effective against both 8226/S and 8226/DX5 cells in a dose and time-dependent manner (p = 0.02) in vitro and promoted cell cycle arrest in S phase in these cells. The tumor volume was lower in mice treated with AZT compared to untreated mice (p = 0.0003). AZT down-regulated the pro-proliferative genes encoding AKT1, MYC, STAT1, MAPK8, MAPK9, CCL-3, Bcl-3, and cyclin D2; pro-angiogenenic genes encoding VEGF and IL8; and genes involved in cell adhesion (ICAM1 and FN1) and the NF-κB pathway. AZT up-regulated the expression of tumor suppressor gene FOXP1 and the pro-apoptotic genes encoding BID, Bcl-10, and caspase-8. Thus, we demonstrated the cytotoxic effect of AZT in human MM cell lines for the first time. Our data may provide the rationale for future clinical trials of AZT for treating MM.
Export Options
About this article
Cite this article as:
Pereira Juliana, Levy Debora, L.M. Ruiz Jorge, A. Brocardo Graciela, A. Ferreira Kleber, O. Costa Renata, G. Queiroz Rodrigo, A. Maria Durvanei, E. Hallack Neto Abrahao, A.F. Chamone Dalton and P. Bydlowski Sergio, Azidothymidine is Effective Against Human Multiple Myeloma: A New Use for an Old Drug?, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (1) . https://dx.doi.org/10.2174/1871520611307010186
DOI https://dx.doi.org/10.2174/1871520611307010186 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical Pharmacology
Current Drug Metabolism Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design The Development of Stem Cell-Based Treatment for Liver Failure
Current Stem Cell Research & Therapy Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors
Current Medicinal Chemistry iPSCs Derived from Malignant Tumor Cells: Potential Application for Cancer Research
Current Stem Cell Research & Therapy Wide-Ranging Genomic Effects of Plasticisers and Related Compounds
Current Drug Metabolism Micro/Nanoparticle Design and Fabrication for Pharmaceutical Drug Preparation and Delivery Applications
Current Drug Therapy Synthesis and Some Reactions of 1-aryl-4-acetyl-5-methyl-1,2,3-triazole Derivatives with Anticonvulsant Activity
Mini-Reviews in Medicinal Chemistry A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia
Current Medicinal Chemistry Human Chorionic Gonadotropin: A Model Molecule For Oligopeptide-Based Drug Discovery
Endocrine, Metabolic & Immune Disorders - Drug Targets Biomarkers in Amyotrophic Lateral Sclerosis: Is There A Neurovascular Pathway?
Current Neurovascular Research Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China
Current Gene Therapy Effect of Contrast-enhanced Contemporaneous <sup>18</sup>F-FDG PET/CT on Semi Quantification Uptake Value Using Third Party Viewing Workstation
Recent Patents on Medical Imaging Skp2 Inhibitors: Novel Anticancer Strategies
Current Medicinal Chemistry Drug Targeting Approaches and Use of Drug Delivery Systems in Management of Cancer
Current Pharmaceutical Design Emergence of Functionalized Nanomedicines in Cancer Chemotherapy: Recent Advancements, Current Challenges and Toxicity Considerations
Recent Patents on Nanomedicine State of the Art of the Therapeutic Perspective of Sorafenib Against Hematological Malignancies
Current Medicinal Chemistry Targeting Hsp90 in Non-Cancerous Maladies
Current Topics in Medicinal Chemistry Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein
Current Medicinal Chemistry Evidence for Predominance of CCR5-Using HIV-1 Strains During Highly Active Antiretroviral Therapy
Current HIV Research